Nordea Investment Management AB Acquires 1,060 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Nordea Investment Management AB boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 10.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,295 shares of the biopharmaceutical company's stock after purchasing an additional 1,060 shares during the period. Nordea Investment Management AB's holdings in Alnylam Pharmaceuticals were worth $3,640,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Bessemer Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 69 shares during the last quarter. Crossmark Global Holdings Inc. bought a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $275,000. Strs Ohio bought a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $7,781,000. GAMMA Investing LLC raised its stake in shares of Alnylam Pharmaceuticals by 14.3% in the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock valued at $166,000 after acquiring an additional 77 shares during the last quarter. Finally, Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $243,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $474.00 on Wednesday. The company has a fifty day moving average price of $457.90 and a two-hundred day moving average price of $356.04. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The firm has a market capitalization of $62.13 billion, a PE ratio of -191.90 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. During the same quarter in the previous year, the business earned ($0.13) EPS. The firm's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the business's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,103,454.05. Following the sale, the executive vice president directly owned 25,231 shares of the company's stock, valued at approximately $11,405,673.55. The trade was a 8.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Pushkal Garg sold 3,022 shares of the business's stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the completion of the sale, the executive vice president directly owned 20,221 shares in the company, valued at $9,129,377.08. This represents a 13.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 in the last ninety days. 1.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ALNY shares. UBS Group lifted their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a report on Friday, August 1st. Citigroup raised their price target on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. The Goldman Sachs Group raised their price target on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a "buy" rating in a report on Tuesday, September 16th. Finally, Needham & Company LLC raised their price target on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Twenty-three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $466.92.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.